Surface Oncology Stock Z Score
SURFDelisted Stock | USD 0.96 0.03 3.23% |
Surface |
Surface Oncology Company Z Score Analysis
Surface Oncology's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
Current Surface Oncology Z Score | -1.33 |
Most of Surface Oncology's fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Surface Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
| |||||||
| |||||||
| |||||||
| |||||||
|
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
CompetitionBased on the company's disclosures, Surface Oncology has a Z Score of -1.33. This is 119.7% lower than that of the Biotechnology sector and 139.82% lower than that of the Health Care industry. The z score for all United States stocks is 115.25% higher than that of the company.
Did you try this?
Run Portfolio Backtesting Now
Portfolio BacktestingAvoid under-diversification and over-optimization by backtesting your portfolios |
All Next | Launch Module |
Surface Fundamentals
Return On Equity | -1.06 | |||
Return On Asset | -0.41 | |||
Current Valuation | 18.31 M | |||
Shares Outstanding | 60.82 M | |||
Shares Owned By Insiders | 7.27 % | |||
Shares Owned By Institutions | 46.03 % | |||
Number Of Shares Shorted | 165.27 K | |||
Price To Earning | 0.64 X | |||
Price To Book | 0.47 X | |||
Price To Sales | 1.60 X | |||
Revenue | 30 M | |||
Gross Profit | (37 M) | |||
EBITDA | (61.87 M) | |||
Net Income | (63.59 M) | |||
Cash And Equivalents | 156.65 M | |||
Cash Per Share | 2.70 X | |||
Total Debt | 56.04 M | |||
Debt To Equity | 0.45 % | |||
Current Ratio | 8.19 X | |||
Book Value Per Share | 0.81 X | |||
Cash Flow From Operations | (59.55 M) | |||
Short Ratio | 0.45 X | |||
Earnings Per Share | (1.66) X | |||
Target Price | 2.38 | |||
Number Of Employees | 35 | |||
Beta | 1.75 | |||
Market Capitalization | 65.69 M | |||
Total Asset | 159.91 M | |||
Retained Earnings | (204.33 M) | |||
Working Capital | 112.88 M | |||
Current Asset | 22 K | |||
Current Liabilities | 36 K | |||
Z Score | -1.33 | |||
Net Asset | 159.91 M |
About Surface Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Surface Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Surface Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Surface Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Surface Stock
If you are still planning to invest in Surface Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Surface Oncology's history and understand the potential risks before investing.
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |